Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Published:2022-02-09 Issue:2 Volume:40 Page:269-279
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Brackman Deanna¹^ORCID,Eckert Doerthe²,Menon Rajeev¹,Salem Ahmed Hamed¹^ORCID,Potluri Jalaja³,Smith B. Douglas⁴,Wei Andrew H.⁵⁶,Hayslip John³,Miles Dale⁷,Mensing Sven²,Gopalakrishnan Sathej²,Zha Jiuhong¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics AbbVie Inc. North Chicago Illinois USA

2. Clinical Pharmacology and Pharmacometrics AbbVie Deutschland GmbH Co. KG Ludwigshafen Germany

3. Oncology Development AbbVie Inc. North Chicago Illinois USA

4. Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA

5. Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Australia

6. Walter and Eliza Hall Institute of Medical Research Melbourne Australia

7. Clinical Pharmacology Genentech Inc. South San Francisco California USA

Funder

AbbVie

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2964

Reference23 articles.

1. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

3. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

4. Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study;2024-07-19

2. Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method;Anti-Cancer Drugs;2024-07-08

3. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia;Cancer Chemotherapy and Pharmacology;2024-05-23

4. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

5. Effect of oral posaconazole on venetoclax plasma concentration and efficacy in patients with acute myeloid leukemia;2024-04-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3